ZVSA
ZyVersa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.10
−0.20%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
173.4%
Return on equity
-3.3%
Return on assets
180.2%
Return on invested capital
0.00x
Asset turnover
-$2.6B
Cash from operations
$3.91
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026